BBOT
NASDAQ
$8.42
BridgeBio Oncology Therapeutics Inc Com (BBOT)
BridgeBio Oncology Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of small molecule inhibitor for cancer patients. The company is headquartered in South San Francisco, California.
Sector:
Healthcare
Industry:
Biotechnology
Strong Buy
Target: $25.30 (+200.48%)
Market Cap
$674M
Free Cash Flow Yield
-11.77%
Beta (5Y)
1.25
Price Chart
Valuation
Market Cap$674M
P/B1.90
Profitability
EBITDA-$169M
EPS-$1.68
Financial Health
Free Cash Flow Yield-11.77%
Growth & Risk
Beta (5Y)1.25
Sharpe Ratio0.08